RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. https://t.co/aAFsf5D3Yk. #Targets21 https://t.co/CIvDS7UAqJ
BRAIN: the IDH1/2 inhibitor vorasidenib was well tolerated and showed some efficacy in a phase 1 study of IDH-mutant low grade glioma. https://t.co/3Q5qfdf3Xt
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
Phase 1 Study: Vorasidenib in recurrent or progressive glioma. https://t.co/k1D0toAzlT https://t.co/Ozt1LMkya1
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/Pn99ZXbUgQ Impressive PFS median 36.8 mos. Potential implication for IDH1/2 cholangiocarcinoma @curecc @CcaEns @CCA_A
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/H4s4SBKdhT
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/9swSaSquCh #gedefo #feedly
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/USWcVLABM1
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive #Glioma. #LGG https://t.co/ALSSObu6wy
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/4lhZglwLPS #BrainTumorThursday
In a recent @AACR clinical trial, Dr. Timothy Cloughesy & other researchers found that Vorasidenib was well tolerated and showed preliminary antitumor activity in patients with lower-grade gliomas. https://t.co/ZkQbby9jZ3 https://t.co/ygkZiQYsgs
#Vorasidenib, a first-in-class brain-penetrant inhibitor of mutant IDH1/2 (mIDH1/2), showed a favorable safety profile and preliminary clinical activity in recurrent or progressive mIDH1/2 #glioma. @DrMartaPPrado https://t.co/hqIJqZotlZ https://t.co/l7Jddo
RT @JBrosnanCashman: Dr. Ingo Mellinghoff is presenting data on the mIDH1/2 inhibitor vorasidenib in patients with low-grade #glioma at #AS…
Dr. Ingo Mellinghoff is presenting data on the mIDH1/2 inhibitor vorasidenib in patients with low-grade #glioma at #ASCO21. For more, read this related #clinicaltrial from Dr. Mellinghoff, now online in @CCR_AACR. @sloan_kettering https://t.co/gdNRJllWw
Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human Phase I trial https://t.co/llZs8VWZDi